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ABSTRACT 
Objective: Typhoid fever is endemic in Albania and is becom- 
ing increasingly resistant to ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole. Perfloxacin has been shown 
to have significant activity in vitro against Salmonella species. 
The authors studied its therapeutic efficacy in patients with 
typhoid fever. 
Methods: Thirty patients with ampicillin-resistant typhoid fever, 
who were admitted to the Infectious Disease Clinic at the Uni- 
versity Hospital Center of Tirana, were enrolled in this prospec- 
tive, nonblinded clinical trial. Patients were treated with oral 
perfloxacin at 400 mg twice daily. They were randomized to 
receive treatment for either 7 days (group I) or 10 days (group II). 
Conclusions: Excellent therapeutic responses were observed in 
all patients in both groups. In every case, there was significant 
clinical improvement with defervescence and sterile blood cul- 
tures by day 4 and three consecutive negative urine and stool 
cultures at the end of treatment. Perfloxacin was highly effec- 
tive in treatment of typhoid fever. Treatment for 7 days appeared 
to be as effective as treatment for IO days. In both groups, bile 
cultures at the end of treatment and at 2 months follow-up 
were sterile, suggesting that both regimens were effective in 
preventing a chronic carrier state. 
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Typhoid fever is endemic in Albania, at times reaching 
epidemic proportions. Salmonella typhi bacilli are 
becoming increasingly resistant to ampicillin, chloram- 
phenicol, and sulfamethoxazole.The resistant strains cause 
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more serious clinical complications and may lead to a 
chronic carrier state. Because of the high incidence of 
resistant strains, there is an urgent need for alternative 
therapies for typhoid fever.The newer quinolones have 
been shown to have significant in vitro activity against 
Salmonella species as well as other enteric pathogens. 
Perfloxacin has bacteriologic and pharmacokinetic prop- 
erties that make it particularly promising for the treat- 
ment of these infections.lW3 In cases of typhoid fever, 7 
days of treatment with perfloxacin has been reported to 
be as effective as 10 days.* 
To evaluate the effectiveness of oral perfloxacin in 
the treatment of typhoid fever due to multiresistant 
strains of S. typhi, a prospective study was done at the 
Department of Infectious Diseases at the University Hos- 
pital Center of Tirana.The purposes of the study were to 
evaluate the effectiveness of oral perfloxacin in the treat- 
ment of infections due to ampicillin-resistant strains of S. 
typhi, to study its efficacy in prevention of a chronic car- 
rier state, and to compare outcomes after treatment for 
7 or 10 days. 
METHODS 
Patients were eligible for this study if they had a positive 
blood culture due to an ampicillin-resistant strain of S. 
typhi, had signs and symptoms of typhoid fever, and had 
not received quinolones in the 2 weeks prior to hospi- 
talization.Treatment was considered successful if all of the 
following cultures were negative for S. typhi: a blood cul- 
ture during treatment, urine and stool cultures on 3 con- 
secutive days following treatment, and bile cultures at 
the end of treatment and at 2-month follow-up. 
Thirty patients, examined between May 1992 and 
February 1994, met the eligibility criteria listed above 
and were enrolled. There were 18 males (60%) and 12 
females (40%); their ages ranged from I6 to 42 years 
(mean, 24 y).The patients were divided into two groups 
of 15. Group I received oral perfloxacin at 400 mg twice 
daily for 7 days, and group II received the same regimen 
for 10 days. Patients were evaluated by interview, physi- 
cal examination, and laboratory testing of blood, urine, 
stool, and bile samples. 
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Table 1. Clinical Findings, at Admission, of the 30 Patients with 
Typhoid Fever 
Symptoms 
Fever 
Headache 
Splenomegaly 
Hepatomegaly 
Anorexia 
Chills 
Diarrhea 
Constipation 
Abdominal pains 
Rose spots 
Nausea or vomiting 
Cough 
Rales 
Cervical adenopathy 
Neurologic manifestations 
Dysuria 
Group I 
n = 15 (100%) 
15 (100) 
12 (80) 
11 (73) 
11 (73) 
Q (60) 
7 (47) 
7 (47) 
7 (47) 
6 (40) 
6 (40) 
5 (33) 
3 (20) 
3 (20) 
2 (13) 
2 (13) 
2 (13) 
Group II 
n = 75 (100%) 
15 (100) 
14 (93) 
12 (80) 
10 (67) 
7 (47) 
Q (60) 
9 (60) 
6 (40) 
7 (47) 
7 (47) 
6 (40) 
3 (20) 
3 (20) 
3 (20) 
3 (20) 
2 (13) 
RESULTS 
The clinical findings in the 30 patients are summarized 
in Table 1. On admission, all of the 30 patients had blood 
cultures that were positive for S. typhi; only 11 (36%) 
had positive urine cultures. Table 2 summarizes the 
antimicrobial susceptibilities of the blood culture iso- 
latesAl of the blood culture strains were sensitive to per- 
floxacin and resistant to ampicillin, 25 strains (83%) were 
resistant to ampicillin and chloramphenicol, 21 strains 
(70%) were resistant to ampicillin and trimethoprim-sul- 
famethoxazole, and 12 strains (40%) were resistant to 
ampicillin, chloramphenicol, and trimethoprim-sul- 
famethoxazole. 
Defervescence began on the second day in ten 
patients (67%) and on the third day in the remaining five 
cases in each group. All patients, in both groups, were 
afebrile by day 5. Blood cultures were sterile by day 3 in 
ten patients (67%) in each group, and in all patients by 
day 4.All stool cultures were negative by the third day of 
treatment. 
Stool and urine cultures for S. typhi were done on 
days 7,8, and 9 for group I and on days 10, 11, and 12 
for group II; all of these cultures were negative. Bile cul- 
tures, performed at completion of treatment and at the 
2-month follow-up, were negative for all patients in both 
groups. No relapses occurred during hospitalization or 
during the subsequent 2 months. 
Treatment with perfloxacin resulted in nausea or 
abdominal discomfort in four patients (13%); however, it 
was not severe enough to warrant discontinuation of the 
drug. Other adverse reactions, such as rash, headache, 
fatigue, insomnia, or diarrhea were not observed. No alter- 
ations of hematologic or biochemical test results were 
seen that could be attributed to perfloxacin. 
DISCUSSION 
Because of the emergence of strains of S. @phi that are 
resistant to ampicillin, patients with typhoid fever are at 
risk of serious clinical complications if they do not 
receive appropriate therapies. The complications may 
include enteric hemorrhage, perforation, pneumonia, 
myocarditis, meningitis, cholecystitis, hepatic or splenic 
abscesses, phlebitis, spondylitis, spondylodiskitis, 
pyomyositis, and acute rhabdomyolysis.5,6 
In this study, patients with typhoid fever due to ampi- 
cillin-resistant strains of S. @phi were treated with a 7- or 
lo-day course of oral perfloxacin at 400 mg twice daily. 
There was an excellent clinical and microbiologic 
response to both regimens. With treatment durations of 
either 7 or 10 days, there was significant clinical improve- 
ment with defervescence and sterile blood cultures by 
day 4, three consecutive negative urine and stool cultures 
at the end of treatment, and negative bile cultures at the 
end of treatment and 2 months later. The 7- and 1 O-day 
regimens were equally safe and effective both in treat- 
ment of the acute illness and in prevention of a chronic 
carrier state. 
Fluoroquinolones are effective against enteric 
pathogens such as Salmonella species, Shigella species, 
and Yersinia species.They have several advantages over 
nalidixic acid, the parent compound of this class of 
antimicrobial agents; these include enhanced bioavail- 
ability with oral administration, reduced protein bind- 
ing, and longer serum half-lives. Because of these 
characteristics, lower and more infrequent doses can be 
given. 
The fluoroquinolones also have the advantage of 
being concentrated within phagocytes and other intra- 
cellular sites favored by pathogens such as Salmonella 
species; the intracellular concentration of peffloxacin may 
be 1.8 to 14 times the serum level.4,7-10This characteristic 
Table 2. Results of Antimicrobial Susceptibility Testing of Isolates of Salmonella typhi from Blood Cultures of 30 
Patients with Typhoid Fever 
Antibiotic Number Resistant (%) 
Ampicillin 
Ampicillin + chloramphenicol 
Ampicillin + trimethoprim-sulfamethoxazole 
Ampicillin + chloramphenicol + trimethoprim-sulfamethoxazole 
Perfloxacin 
30 (100) 
25 (83) 
21 (70) 
12 (40) 
0 (0) 
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may be critical for eradication of an enteric pathogen 
from intracellular sites within the intestinal or biliary 
tracts.l’ 
CONCLUSION 
Perfloxacin, because it is well tolerated, has significant 
pharmacokinetic advantages, and is highly effective in 
this indication, should be considered for use in cases of 
ampicillin-resistant typhoid fever.Treatment with 400 mg 
twice daily for 7 days appears to be safe and effective 
for typhoid fever.This regimen produced prompt relief 
from the acute symptoms of the infection and seemed to 
reduce the risk of its recurrence. 
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